|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM138 |
Gene summary for TMEM138 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM138 | Gene ID | 51524 |
| Gene name | transmembrane protein 138 | |
| Gene Alias | HSPC196 | |
| Cytomap | 11q12.2 | |
| Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | J3QSZ6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51524 | TMEM138 | LZE2T | Human | Esophagus | ESCC | 4.31e-02 | 4.06e-01 | 0.082 |
| 51524 | TMEM138 | LZE4T | Human | Esophagus | ESCC | 1.11e-10 | 1.82e-01 | 0.0811 |
| 51524 | TMEM138 | LZE5T | Human | Esophagus | ESCC | 4.73e-02 | 1.91e-01 | 0.0514 |
| 51524 | TMEM138 | LZE7T | Human | Esophagus | ESCC | 8.57e-09 | 3.07e-01 | 0.0667 |
| 51524 | TMEM138 | LZE8T | Human | Esophagus | ESCC | 1.85e-04 | 2.36e-01 | 0.067 |
| 51524 | TMEM138 | LZE22T | Human | Esophagus | ESCC | 2.84e-05 | 2.20e-01 | 0.068 |
| 51524 | TMEM138 | LZE24T | Human | Esophagus | ESCC | 1.15e-27 | 6.19e-01 | 0.0596 |
| 51524 | TMEM138 | LZE6T | Human | Esophagus | ESCC | 5.61e-07 | 2.51e-01 | 0.0845 |
| 51524 | TMEM138 | P2T-E | Human | Esophagus | ESCC | 1.05e-33 | 5.80e-01 | 0.1177 |
| 51524 | TMEM138 | P4T-E | Human | Esophagus | ESCC | 1.94e-38 | 7.81e-01 | 0.1323 |
| 51524 | TMEM138 | P5T-E | Human | Esophagus | ESCC | 2.83e-24 | 5.26e-01 | 0.1327 |
| 51524 | TMEM138 | P8T-E | Human | Esophagus | ESCC | 4.58e-23 | 4.22e-01 | 0.0889 |
| 51524 | TMEM138 | P9T-E | Human | Esophagus | ESCC | 4.29e-21 | 4.19e-01 | 0.1131 |
| 51524 | TMEM138 | P10T-E | Human | Esophagus | ESCC | 2.47e-20 | 3.71e-01 | 0.116 |
| 51524 | TMEM138 | P11T-E | Human | Esophagus | ESCC | 5.96e-26 | 9.05e-01 | 0.1426 |
| 51524 | TMEM138 | P12T-E | Human | Esophagus | ESCC | 1.46e-17 | 3.98e-01 | 0.1122 |
| 51524 | TMEM138 | P15T-E | Human | Esophagus | ESCC | 6.42e-15 | 2.40e-01 | 0.1149 |
| 51524 | TMEM138 | P16T-E | Human | Esophagus | ESCC | 2.05e-16 | 3.36e-01 | 0.1153 |
| 51524 | TMEM138 | P17T-E | Human | Esophagus | ESCC | 8.51e-16 | 4.49e-01 | 0.1278 |
| 51524 | TMEM138 | P19T-E | Human | Esophagus | ESCC | 1.10e-05 | 5.88e-01 | 0.1662 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM138 | SNV | Missense_Mutation | c.482G>T | p.Arg161Leu | p.R161L | Q9NPI0 | protein_coding | deleterious(0.01) | benign(0.169) | TCGA-R2-A69V-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| TMEM138 | SNV | Missense_Mutation | rs202210746 | c.307C>T | p.Arg103Cys | p.R103C | Q9NPI0 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| TMEM138 | SNV | Missense_Mutation | rs781769843 | c.308N>A | p.Arg103His | p.R103H | Q9NPI0 | protein_coding | tolerated(0.22) | probably_damaging(0.982) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| TMEM138 | SNV | Missense_Mutation | c.354G>A | p.Met118Ile | p.M118I | Q9NPI0 | protein_coding | tolerated(0.33) | benign(0) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMEM138 | SNV | Missense_Mutation | rs141029883 | c.415N>A | p.Val139Ile | p.V139I | Q9NPI0 | protein_coding | tolerated(0.33) | benign(0.003) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| TMEM138 | SNV | Missense_Mutation | novel | c.178N>C | p.Phe60Leu | p.F60L | Q9NPI0 | protein_coding | tolerated(0.19) | benign(0.003) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM138 | SNV | Missense_Mutation | c.275N>T | p.Ser92Ile | p.S92I | Q9NPI0 | protein_coding | deleterious(0) | probably_damaging(0.948) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TMEM138 | SNV | Missense_Mutation | c.341N>C | p.Asp114Ala | p.D114A | Q9NPI0 | protein_coding | tolerated(0.12) | benign(0.029) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMEM138 | SNV | Missense_Mutation | c.223T>G | p.Phe75Val | p.F75V | Q9NPI0 | protein_coding | tolerated(0.62) | benign(0.001) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMEM138 | SNV | Missense_Mutation | c.58N>C | p.Tyr20His | p.Y20H | Q9NPI0 | protein_coding | tolerated(0.2) | possibly_damaging(0.885) | TCGA-G3-A3CK-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |